Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Tardive Dyskinesia Treatment Industry?
The market for treating tardive dyskinesia has seen significant growth recently, and this trend is expected to continue, with its worth escalating from $2.40 billion in 2024 to $2.61 billion in 2025, at a compound annual growth rate (CAGR) of 8.7%. The recent growth recorded can be associated to the heightened utilization of antipsychotic medications, increased awareness about drug-related movement disorders, a surge in schizophrenia and bipolar disorders, the rise in off-label usage of antipsychotics, and an expanding elderly population using psychotropic drugs.
The market for tardive dyskinesia treatments is predicted to experience robust growth in the coming years, reaching a total value of $3.61 billion in 2029 with a CAGR of 8.4%. This anticipated growth in the forecast period is due to factors such as an increasing demand for safer antipsychotic therapies, greater awareness raised by advocacy and educational campaigns, a shift towards individualized mental health treatments, increased healthcare expenditure on neurological and psychiatric conditions, and a rise in the number of patients undergoing long-term psychiatric therapy. Major emerging trends for this upcoming period include the development of neuroprotective strategies, creation of dual-action therapies, inclusion of real-world evidence in drug assessment, incorporation of digital biomarkers, and advancements in non-dopaminergic therapeutics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27431&type=smp
What Forces Are Driving The Growth Of The Tardive Dyskinesia Treatment Industry?
The escalating rates of mental health conditions are set to boost the expansion of the tardive dyskinesia treatment market. Mental illnesses encompass a broad spectrum of conditions impacting an individual’s emotions, cognitive functions, behaviors, and everyday activities, generally necessitating professional diagnosis and intervention. The rising incidences of mental conditions are linked to the increase in stress and lifestyle strains derived from demanding job responsibilities, social disconnection, and scarce self-care time. Tardive dyskinesia therapy aids in controlling involuntary motion symptoms, enhancing the treatment results and lifestyle quality for people with mental health disorders who are on extended antipsychotic drugs. For example, the House of Commons Library, a research and information facility in the UK, reported in March 2024 that the ratio of 17- to 19-year-olds with a likely mental disorder climbed from 17% in 2021 to 26% in 2022. Hence, the escalating incidence of mental illnesses is accelerating the expansion of the tardive dyskinesia treatment market.
What Is The Overview Of Market Segmentation In The Tardive Dyskinesia Treatment Industry?
The tardive dyskinesia treatment market covered in this report is segmented
1) By Treatment Type: Medications, Botulinum Toxin Injections, Deep Brain Stimulation, Other Treatment Types
2) By Drug: Valbenazine, Amantadine, Tetrabenazine, Clonazepam, Other Drugs
3) By Route Of Administration: Oral Administration, Injection, Transdermal Patches
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medications: Antipsychotic Medications, Benzodiazepines, Dopamine-Depleting Agents, Anticholinergic Agents
2) By Botulinum Toxin Injections: Facial Muscle Injections, Neck Muscle Injections, Limb Muscle Injections, Customized Injection Protocols
3) By Deep Brain Stimulation: Subthalamic Nucleus Stimulation, Globus Pallidus Interna Stimulation, Thalamic Stimulation, Multi-Target Stimulation
4) By Other Treatment Types: Supportive Therapies, Cognitive Behavioral Therapy, Physical Rehabilitation, Emerging Experimental Treatments
What Future Market Trends Are Projected For The Tardive Dyskinesia Treatment Industry?
Key companies in the tardive dyskinesia treatment market are focusing their efforts on the creation of innovative drugs like sprinkle capsule formulations. This step is aimed at enhancing medication adherence in patients struggling with swallowing difficulties. The sprinkle capsule formulation is specially designed to be poured onto soft food, making it more swallow-friendly for patients who have dysphagia or face struggles with swallowing complete capsules. For instance, in July 2024, Ingrezza sprinkle (valbenazine) capsules were introduced to the market by Neurocrine Biosciences Inc., a biotech firm based in the US. These capsules, which are the most frequently prescribed vesicular monoamine transporter 2 (VMAT2) inhibitors, are used to treat adults suffering from tardive dyskinesia and chorea, which is associated with Huntington’s disease. By controlling dopamine levels in the brain, this VMAT2 inhibitor helps handle involuntary movements. The medication comes as a one-dose daily oral capsule, including a sprinkle formulation made to simplify administration for those patients who have trouble swallowing.
Who Are The Primary Players Operating Across The Global Tardive Dyskinesia Treatment Market?
Major companies operating in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, SteriMax Inc., Adamas Pharmaceuticals Inc., ChemWerth Inc, Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Synnat Pharma Pvt. Ltd, LGM Pharma LLC, and SOM Biotech S.A.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-treatment-global-market-report
Which Region Offers The Most Growth Potential For The Tardive Dyskinesia Treatment Market Through 2029?
North America was the largest region in the tardive dyskinesia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27431&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model